HYDERABAD: Despite posting document revenues, pharma main Dr Reddy’s Laboratories on Thursday reported a marginal 2% enhance in consolidated revenue after tax (PAT attributable to fairness holders) at Rs 1414.3 crore as in comparison with Rs 1,379 crore in the corresponding quarter of final fiscal 12 months.
The firm posted a 16% jump in revenues at almost Rs 8,359 crore for Q3FY25 as in opposition to round Rs 7,215 crore in Q3FY24 thanks in half to a Rs 605 crore income enhance offered to Europe enterprise by the nicotine alternative remedy enterprise of Haleon Plc acquired in the primary quarter of FY25.
Revenues from international generics rose 17% to Rs 7,375 crore through the quarter from Rs 6,309.5 crore in Q3FY24 with the European market accounting for a 143% jump from Rs 497 crore in Q3FY24 to Rs 1209.6 crore in Q3FY25 because of NRT.
However, revenues from the North American market, which accounted for a piece of general international generics revenues, slid 1% to Rs 3383 crore in Q3FY25 from Rs 3349 crore in the identical quarter of FY24.
The firm’s revenues from the Indian market rose 14% to Rs 1346 crore as in opposition to Rs 1180 crore in Q3FY24 and that from rising markets grew 12% to Rs 1436 crore from Rs 1283 crore.
Dr Reddy’s co-chairman & managing director GV Prasad attributed the double digit progress to the newly acquired NRT enterprise, new launches and improved operational efficiencies.
